Literature DB >> 25506513

TB Vaccines: The (Human) Challenge Ahead.

David A Hokey1.   

Abstract

Entities:  

Year:  2014        PMID： 25506513      PMCID： PMC4262929          DOI： 10.4172/2161-1068.1000e128

Source DB:  PubMed          Journal:  Mycobact Dis


× No keyword cloud information.
  14 in total

1.  The ethical challenge of infection-inducing challenge experiments.

Authors:  F G Miller; C Grady
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

2.  Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity.

Authors:  Daniel F Hoft; Shewangizaw Worku; Beate Kampmann; Christopher C Whalen; Jerrold J Ellner; Christina S Hirsch; Robin B Brown; Rhonda Larkin; Qing Li; Hyun Yun; Richard F Silver
Journal:  J Infect Dis       Date:  2002-10-23       Impact factor: 5.226

3.  Clinical reactogenicity of intradermal bacille Calmette-Guérin vaccination.

Authors:  D F Hoft; C Leonardi; T Milligan; G T Nahass; B Kemp; S Cook; J Tennant; M Carey
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

4.  A 2020 vision for vaccines against HIV, tuberculosis and malaria.

Authors:  Rino Rappuoli; Alan Aderem
Journal:  Nature       Date:  2011-05-26       Impact factor: 49.962

Review 5.  Experimental human challenge infections can accelerate clinical malaria vaccine development.

Authors:  Robert W Sauerwein; Meta Roestenberg; Vasee S Moorthy
Journal:  Nat Rev Immunol       Date:  2011-01       Impact factor: 53.106

6.  Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.

Authors:  Sócrates Herrera; Yezid Solarte; Alejandro Jordán-Villegas; Juan Fernando Echavarría; Leonardo Rocha; Ricardo Palacios; Oscar Ramírez; Juan D Vélez; Judith E Epstein; Thomas L Richie; Myriam Arévalo-Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

7.  Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial.

Authors:  Kirsten E Lyke; Matthew Laurens; Matthew Adams; Peter F Billingsley; Adam Richman; Mark Loyevsky; Sumana Chakravarty; Christopher V Plowe; B Kim Lee Sim; Robert Edelman; Stephen L Hoffman
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

8.  Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.

Authors:  Angela M Minassian; Edward O Ronan; Hazel Poyntz; Adrian V S Hill; Helen McShane
Journal:  PLoS One       Date:  2011-05-24       Impact factor: 3.240

9.  A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin.

Authors:  Angela M Minassian; Iman Satti; Ian D Poulton; Joel Meyer; Adrian V S Hill; Helen McShane
Journal:  J Infect Dis       Date:  2012-04-01       Impact factor: 7.759

10.  Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.

Authors:  Helen A Fletcher; Rachel Tanner; Robert S Wallis; Joel Meyer; Zita-Rose Manjaly; Stephanie Harris; Iman Satti; Richard F Silver; Dan Hoft; Beate Kampmann; K Barry Walker; Hazel M Dockrell; Uli Fruth; Lew Barker; Michael J Brennan; Helen McShane
Journal:  Clin Vaccine Immunol       Date:  2013-08-28
View more
  3 in total

Review 1.  Zika virus vaccines.

Authors:  Peter Abbink; Kathryn E Stephenson; Dan H Barouch
Journal:  Nat Rev Microbiol       Date:  2018-10       Impact factor: 60.633

Review 2.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

3.  Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

Authors:  A J Graves; D A Hokey
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.